surpass cvot tirzepatide results Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT SURPASS-CVOT Published: Large Trial Confirms

Researchers can anticipate that the 9mg data will fill the gap between the 8mg and 12mg tiers, potentially identifying an optimal dose that balances efficacy and tolerability better than either existing data point

Saxena R, Hivert MF, Langenberg C, Tanaka T, Pankow JS, Vollenweider P, Lyssenko V, Bouatia-Naji N, Dupuis J, Jackson AU, et al

These effects may overlap with the gastrointestinal side effects of diabetes medications, creating additive discomfort

Severe Complications for Elderly: In individuals who are over 60 years of age, a common cause of papillitis is temporal arteritis (giant cell arteritis)

Tirzepatide is a powerful tool, but weight loss If youre taking tirzepatide and not losing weight or not losing as much as you hoped it can feel confusing and discouraging

Mounjaro: 235500 per month (private) Wegovy: 170300 per month Ozempic: 150200 per month (for diabetes dosing) Private clinics are often the main route for non-diabetic weight management